EZH2 and B-cell non-Hodgkin lymphoma: Hence, analyzing the H4M modification patterns in individual tumors may aid in the development of more effective immunotherapy strategies.206 Tazemetostat, an inhibitor of EZH2, has been developed for the treatment of B-cell lymphomas.